Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)
Topic
505(b)(2)
Hybrid applications, reliance strategy, bridging data, and commercial use cases between full NDA and ANDA.
Approvals· June 8, 2026 · 9 min read
FDA drug-device combination product pathway: PMOA and launch strategy
Generics· May 6, 2026 · 3 min read
Generic entry, ANDA, and 505(b)(2): the commercial difference
By Ran Chen#Generics#505(b)(2)#Orange Book